帕金森病早期<em>SNCA</em>基因Ala53Thr碱基替换对小鼠模型嗅球组织中内源性代谢产物表达的影响

doi:10.3969/j.issn.1672-6731.2021.06.012

摘要/Abstract

摘要：

目的探讨SNCA基因在帕金森病早期病理生理学机制中的作用。方法选择SNCA基因Ala53Thr碱基替换小鼠和野生型小鼠各10只，采用超高效液相色谱-串联质谱（HPLC-MS/MS）法分离嗅球组织代谢产物，采用主成分分析、判别分析、聚类分析等筛选并验证代谢产物，代谢组学分析嗅球组织内源性代谢产物，并构建代谢通路图和网络图以明确相关代谢通路及差异内源性代谢产物之间的关系。结果最终确定29个变量为差异代谢产物，其中，内源性代谢产物磷脂酰胆碱、磷脂酰乙醇胺、维生素C、鞘磷脂、磷脂酰甘油和谷氨酸相对表达量在TG组有所上升（均P<0.05），且上述代谢产物的相对表达量与下调的差异代谢产物之间呈负相关；而磷脂、牛磺酸、缬氨酸、神经酰胺和γ-氨基丁酸（GABA）相对表达量在TG组有所下降（均P<0.05），且上述代谢产物的相对表达量之间呈正相关。相关代谢通路主要涉及牛磺酸和亚牛磺酸代谢通路，谷氨酰胺和谷氨酸代谢通路，维生素C代谢通路，磷脂酰甘油代谢通路，丙氨酸、天冬氨酸和谷氨酸代谢通路，包括牛磺酸、D-谷氨酸、维生素C、卵磷脂、溶血性磷脂酰胆碱[18：2（9Z，12Z）]和GABA共6种标志性代谢成分。结论本研究验证帕金森病早期即可出现嗅球组织病理变化，SNCA基因Ala53Thr碱基替换的直接作用导致磷脂类代谢改变，并引起神经功能紊乱。

关键词: 帕金森病, &alpha, 突触核蛋白, 基因, 突变, 代谢组学, 嗅球, 色谱法, 液相

Abstract:

Objective To explore the pathophysiologic mechanism of SNCA gene in the early-stage of Parkinson's disease (PD). Methods Wild type (WT group, n=10) and SNCA Ala53Thr base substitution mice (TG group, n=10) were selected for further experiments. Endogenous metabolites in olfactory bulb (OB) of transgenic and wild type mice were detected and analyzed by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Then the endogenous metabolites were identified through mzCloud and determined by molecular formula and molecular weight. The differential endogenous metabolites were obtained by principal component analysis (PCA), partial least squares discrimination analysis (PLS-DA), orthogonal partial least squares discriminant analysis (OPLS-DA) and cluster analysis. Finally, the pathway and interaction network between the differential endogenous metabolites and corresponding pathways were constructed. Results Finally 29 variations were identified as differential metabolites. Among them, the relative expressions of phosphatidylcholine (PC), phosphatidylethanolamine (PE), vitamin C, sphingomyelin (SM), phosphatidylglycerol (PG) and glutamic acid were elevated in TG group (P<0.05, for all) and the negative relationship was shown between elevated metabolite and decreased metabolite in relative expression, while the relative expressions of phosphalipids, taurine, ceramide valine and γ-aminobutyric acid (GABA) were decreased in TG group (P<0.05, for all) and the relationship of relative expression among them was positive. The related metabolic pathways were mainly associated with the taurine and hypotaurine metabolism, glutamine and glutamate metabolism, ascorbate and aldarate metabolism, glycerophospholipid metabolism and alanine, aspartate and glutamate metabolism, included taurine, D -glutamate, vitamine C, phospholipid, LysoPC[18:2 (9Z, 12Z)] and GABA all 6 significant metabolites. Conclusions The experiment verified pathological changes of OB in the early stage of PD. Meanwhile the differences in phosphatides could be a direct result of SNCA Ala53Thr mutation. Furthermore, malfunction of neurons in OB is also observed and may be contributed to the abnormal phosphatides' metabolism.

Key words: Parkinson disease, alpha-Synuclein, Genes, Mutation, Metabolomics, Olfactory bulb, Chromatography, liquid

陈宁, 隋云鹏, 孟凡刚. 帕金森病早期SNCA基因Ala53Thr碱基替换对小鼠模型嗅球组织中内源性代谢产物表达的影响[J]. 中国现代神经疾病杂志, 2021, 21(6): 493-501.

CHEN Ning, SUI Yun-peng, MENG Fan-gang. Study on changes of endogenous metabolites in olfactory bulb of early-stage Parkinson's disease induced by SNCA gene Ala53Thr base substitution in mice[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2021, 21(6): 493-501.

http://journal11.magtechjournal.com/cjcnn/CN/Y2021/V21/I6/493

参考文献

[1] Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease:diagnosis and management[J]. Lancet Neurol, 2006, 5:235-245.
[2] Haehner A, Hummel T, Reichmann H. A clinical approach towards smell loss in Parkinson's disease[J]. J Parkinsons Dis, 2014, 4:189-195.
[3] Perez-Pardo P, Kliest T, Dodiya HB, Broersen LM, Garssen J, Keshavarzian A, Kraneveld AD. The gut-brain axis in Parkinson's disease:possibilities for food-based therapies[J]. Eur J Pharmacol, 2017, 817:86-95.
[4] White AJ, Wijeyekoon RS, Scott KM, Gunawardana NP, Hayat S, Solim IH, McMahon HT, Barker RA, Williams -Gray CH. The peripheral inflammatory response to alpha-synuclein and endotoxin in Parkinson's disease[J]. Front Neurol, 2018, 9:946.
[5] Wang C, Ma Z, Yan DY, Liu C, Deng Y, Liu W, Xu ZF, Xu B. Alpha-synuclein and calpains disrupt SNARE-Mediated synaptic vesicle fusion during manganese exposure in SH-SY5Y cells[J]. Cells, 2018, 7:258.
[6] Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, Singleton A, Olanow CW, Merchant KM, Bezard E, Petsko GA, Meissner WG. Targeting α-synuclein for treatment of Parkinson's disease:mechanistic and therapeutic considerations[J]. Lancet Neurol, 2015, 14:855-866.
[7] Prots I, Grosch J, Brazdis RM, Simmnacher K, Veber V, Havlicek S, Hannappel C, Krach F, Krumbiegel M, Schütz O, Reis A, Wrasidlo W, Galasko DR, Groemer TW, Masliah E, Schlötzer-Schrehardt U, Xiang W, Winkler J, Winner B. α-Synuclein oligomers induce early axonal dysfunction in human iPSC -based models of synucleinopathies[J]. Proc Natl Acad Sci USA, 2018, 115:7813-7818.
[8] Zhang G, Xia Y, Wan F, Ma K, Guo X, Kou L, Yin S, Han C, Liu L, Huang J, Xiong N, Wang T. New perspectives onroles of alpha-synuclein in Parkinson's disease[J]. Front Aging Neurosci, 2018, 10:370.
[9] Verhoeven A, Giera M, Mayboroda OA. KIMBLE:a versatile visual NMR metabolomics workbench in KNIME[J]. Anal Chim Acta, 2018, 1044:66-76.
[10] Hussein M, Han ML, Zhu Y, Schneider-Futschik EK, Hu X, Zhou QT, Lin YW, Anderson D, Creek DJ, Hoyer D, Li J, Velkov T. Mechanistic insights from Global Metabolomics Studies into synergistic bactericidal effect of a Polymyxin B combination with Tamoxifen against cystic fibrosis MDR Pseudomonas aeruginosa[J]. Comput Struct Biotechnol J, 2018, 16:587-599.
[11] Gomes RLE, Gebrim EMMS. Metabolomics of thyroid nodules and the future[J]. Arch Endocrinol Metab, 2018, 62:493-494.
[12] Stopschinski BE, Holmes BB, Miller GM, Manon VA, Vaquer-Alicea J, Prueitt WL, Hsieh-Wilson LC, Diamond MI. Specific glycosaminoglycan chain length and sulfation patterns are required for cell uptake of tau versus α-synuclein and β-amyloid aggregates[J]. J Biol Chem, 2018, 293:10826-10840.
[13] Iljina M, Dear AJ, Garcia GA, De S, Tosatto L, Flagmeier P, Whiten DR, Michaels TCT, Frenkel D, Dobson CM, Knowles TPJ, Klenerman D. Quantifying Co-Oligomer formation by α-synuclein[J]. ACS Nano, 2018, 12:10855-10866.
[14] Iwasaki Y, Deguchi A, Mori K, Ito M, Kawai Y, Akagi A, Mimuro M, Miyahara H, Yoshida M. Autopsied centenarian case of Alzheimer's disease combined with hippocampal sclerosis, TDP-43, and α-synuclein pathologies[J]. Neuropathology, 2018, 38:653-659.
[15] Chen H, McCaffery JM, Chan DC. Mitochondrial fusion protects against neurodegeneration in the cerebellum[J]. Cell, 2007, 130:548-562.
[16] Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, Cao S, Caldwell KA, Caldwell GA, Marsischky G, Kolodner RD, Labaer J, Rochet JC, Bonini NM, Lindquist S. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models[J]. Science, 2006, 313:324-328.
[17] Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein[J]. Neuron, 2002, 34:521-533.
[18] Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, Price DL, Lee MK. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death[J]. J Neurosci, 2006, 26:41-50.
[19] Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, Choi P, Wolozin B, Farrer M, Hardy J, Cookson MR. Parkin protects against the toxicity associated with mutant alpha-synuclein:proteasome dysfunction selectively affects catecholaminergic neurons[J]. Neuron, 2002, 36:1007-1019.
[20] Çelebier M, Ibáñez C, Simó C, Cifuentes A. A foodomics approach:CE -MS for comparative metabolomics of colon cancer cells treated with dietary polyphenols[J]. Methods Mol Biol, 2019, 1855:303-313.
[21] Graham SF, Rey NL, Yilmaz A, Kumar P, Madaj Z, Maddens M, Bahado-Singh RO, Becker K, Schulz E, Meyerdirk LK, Steiner JA, Ma J, Brundin P. Biochemical profiling of the brain and blood metabolome in a mouse model of prodromal Parkinson's disease reveals distinct metabolic profiles[J]. J Proteome Res, 2018, 17:2460-2469.
[22] Jenco JM, Rawlingson A, Daniels B, Morris AJ. Regulation of phospholipase D2:selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins[J]. Biochemistry, 1998, 37:4901-4909.
[23] Watanabe H, Yokozeki T, Yamazaki M, Miyazaki H, Sasaki T, Maehama T, Itoh K, Frohman MA, Kanaho Y. Essential role for phospholipase D2 activation downstream of ERK MAP kinase in nerve growth factor-stimulated neurite outgrowth from PC12 cells[J]. J Biol Chem, 2004, 279:37870-37877.
[24] Payton JE, Perrin RJ, Woods WS, George JM. Structural determinants of PLD2 inhibition by alpha-synuclein[J]. J Mol Biol, 2004, 337:1001-1009.
[25] Jenner P. Presymptomatic detection of Parkinson's disease[J]. J Neural Transm Suppl, 1993, 40:23-36.
[26] Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, Reichmann H. Detection of presymptomatic Parkinson's disease:combining smell tests, transcranial sonography, and SPECT[J]. Mov Disord, 2004, 19:1196-1202.
[27] Trezzi JP, Galozzi S, Jaeger C, Barkovits K, Brockmann K, Maetzler W, Berg D, Marcus K, Betsou F, Hiller K, Mollenhauer B. Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease[J]. Mov Disord, 2017, 32:1401-1408.
[28] Stoessel D, Schulte C, Teixeira Dos Santos MC, Scheller D, Rebollo-Mesa I, Deuschle C, Walther D, Schauer N, Berg D, Nogueira da Costa A, Maetzler W. Promising metabolite profiles in the plasma and CSF of early clinical Parkinson's disease[J]. Front Aging Neurosci, 2018, 10:51.

选择文件类型/文献管理软件名称

选择包含的内容

2 帕金森病早期SNCA基因Ala53Thr碱基替换对小鼠模型嗅球组织中内源性代谢产物表达的影响

Study on changes of endogenous metabolites in olfactory bulb of early-stage Parkinson's disease induced by SNCA gene Ala53Thr base substitution in mice

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	范咏言, 李晓欢, 马建军, 杨大伟, 梁可可, 石小雪. 帕金森病患者血清胆红素与睡眠障碍相关分析[J]. 中国现代神经疾病杂志, 2023, 23(8): 723-729.
[2]	任修德, 李涛, 范吉康, 王希森, 贾晓丹, 杨学军. 胶质母细胞瘤FGFR3-TACC3融合基因介导丙酮酸激酶M2入核促进DNA损伤修复基础研究[J]. 中国现代神经疾病杂志, 2023, 23(8): 745-757.
[3]	吴旭玲, 张安妮, 雷晓阳, 冯占辉, 王维, 贺电. 强直性肌营养不良症1型一例[J]. 中国现代神经疾病杂志, 2023, 23(8): 765-769.
[4]	侯玮佳, 于洋, 吴璠, 王玥, 朱志中, 巫嘉陵. 早期帕金森病患者起步异常定量分析[J]. 中国现代神经疾病杂志, 2023, 23(7): 627-632.
[5]	李跃文, 褚先舟, 李娟, 秦艳, 吴桐, 陈先文. BSCL2基因c.455A>G突变致远端型遗传性运动神经病V型一家系[J]. 中国现代神经疾病杂志, 2023, 23(7): 643-647.
[6]	杜倩, 邓素君, 邹姗, 金珺, 周青山. 宏基因组第二代测序技术在重症中枢神经系统感染中的应用[J]. 中国现代神经疾病杂志, 2023, 23(6): 479-484.
[7]	邵暇荔, 张泳, 金莉蓉, 王剑. 震颤为主型帕金森病与特发性震颤患者脑灌注对比分析[J]. 中国现代神经疾病杂志, 2023, 23(6): 542-548.
[8]	王敏, 秦洁, 李岚昕, 李欣, 陈蕾. 2型糖尿病增加帕金森病风险相关机制研究进展[J]. 中国现代神经疾病杂志, 2023, 23(6): 566-570.
[9]	崔立立, 纪坤乾, 张正华, 张同霞, 赵玉英. 以排尿困难发病的SOD1基因变异致肌萎缩侧索硬化一例[J]. 中国现代神经疾病杂志, 2023, 23(5): 472-476.
[10]	蔡洪钱, 张安妮, 徐子茜, 龚慧蓝, 曾红梅, 贺电. 伴PSEN2基因V214L突变的早发型阿尔茨海默病一家系临床研究[J]. 中国现代神经疾病杂志, 2023, 23(4): 335-340.
[11]	徐蓉, 宁泽淑, 康庆云, 陈波, 廖红梅, 杨理明, 吴丽文. 钾离子通道基因变异相关婴儿癫痫性脑病临床表型与基因变异特点分析[J]. 中国现代神经疾病杂志, 2023, 23(3): 196-204.
[12]	唐薇婷, 肖波. N-甲基-D-天冬氨酸受体GRIN2A基因变异与癫痫研究进展[J]. 中国现代神经疾病杂志, 2023, 23(2): 89-93.
[13]	李字林, 胡文瀚, 张凯. 癫痫外科常见病理类型体细胞突变研究进展[J]. 中国现代神经疾病杂志, 2023, 23(2): 115-123.
[14]	刘培培, 巫嘉陵. 基于视频信息的帕金森病智能辅助诊断与治疗进展[J]. 中国现代神经疾病杂志, 2023, 23(1): 35-39.
[15]	姚盈盈, 王雷明, 滕梁红. 脑胶质瘤DNA甲基化临床意义及研究进展[J]. 中国现代神经疾病杂志, 2022, 22(9): 823-828.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 帕金森病早期SNCA基因Ala53Thr碱基替换对小鼠模型嗅球组织中内源性代谢产物表达的影响

Study on changes of endogenous metabolites in olfactory bulb of early-stage Parkinson's disease induced by SNCA gene Ala53Thr base substitution in mice

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价